These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 32986306)

  • 1. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
    Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
    Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
    Otsubo K; Kishimoto J; Kenmotsu H; Minegishi Y; Ichihara E; Shiraki A; Kato T; Atagi S; Horinouchi H; Ando M; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakanishi Y; Okamoto I
    Clin Lung Cancer; 2018 Jan; 19(1):e5-e9. PubMed ID: 28687482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
    Ikeda S; Ogura T; Kato T; Kenmotsu H; Agemi Y; Tokito T; Ito K; Isomoto K; Takiguchi Y; Yoneshima Y; Yokoyama T; Harada T; Tanzawa S; Kobayashi N; Iwasawa T; Misumi T; Okamoto H
    Ann Am Thorac Soc; 2024 Apr; 21(4):635-643. PubMed ID: 38364204
    [No Abstract]   [Full Text] [Related]  

  • 7. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
    Otsubo K; Kishimoto J; Ando M; Kenmotsu H; Minegishi Y; Horinouchi H; Kato T; Ichihara E; Kondo M; Atagi S; Tamiya M; Ikeda S; Harada T; Takemoto S; Hayashi H; Nakatomi K; Kimura Y; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakagawa K; Nakanishi Y; Okamoto I
    Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35361630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
    Iwata T; Yoshida S; Fujiwara T; Wada H; Nakajima T; Suzuki H; Yoshino I
    Ann Thorac Surg; 2016 Dec; 102(6):1905-1910. PubMed ID: 27546601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review.
    Grodkiewicz M; Koziel P; Chmielewska I; Korbel MA; Milanowski J
    Curr Oncol; 2022 Jul; 29(7):5077-5083. PubMed ID: 35877261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.
    Iwata T; Yoshida S; Nagato K; Nakajima T; Suzuki H; Tagawa T; Mizobuchi T; Ota S; Nakatani Y; Yoshino I
    Surg Today; 2015 Oct; 45(10):1263-70. PubMed ID: 25412984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Miura Y; Saito T; Tanaka T; Takoi H; Yatagai Y; Inomata M; Nei T; Saito Y; Gemma A; Azuma A
    Respir Investig; 2018 Jan; 56(1):72-79. PubMed ID: 29325685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis.
    Sekihara K; Aokage K; Miyoshi T; Tane K; Ishii G; Tsuboi M
    Surg Today; 2020 Aug; 50(8):905-911. PubMed ID: 32144483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosis-like lesions and nonspecific interstitial pneumonia.
    Sakamoto S; Shimizu H; Isshiki T; Nakamura Y; Kurosaki A; Isobe K; Homma S
    Clin Respir J; 2021 Mar; 15(3):272-279. PubMed ID: 33058535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
    Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
    PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.